(
ISAB's first US patent application was submitted on
PreciseInhale® delivers exceptionally precise preclinical data that significantly reduces risk in inhaled drug development. It is currently being trialled for clinical use in humans.
ISAB CEO Manoush Masarrat: "The US is a major market with a dynamic, innovative sector and being a key market for ISAB, we have increased our commercial efforts there heavily during the first half of 2021. This patent extension, together with the ongoing clinical validation of PreciseInhale®, will enable us to offer customers in the US a unique aerosol research platform throughout the coming decades."
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About
https://news.cision.com/inhalation-sciences/r/inhalations-sciences--us-patent-extended-until-2034,c3396083
https://mb.cision.com/Main/15842/3396083/1453786.pdf
(c) 2021 Cision. All rights reserved., source